(Q34593276)

English

Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 August 2017

Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study (English)

1 reference

Europe PubMed Central

3 August 2017

0 references

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

5

object named as

Guido Marcucci

1 reference

Europe PubMed Central

3 August 2017

Clara D. Bloomfield

10

object named as

Clara D Bloomfield

1 reference

Europe PubMed Central

3 August 2017

Krzysztof Mrózek

3

object named as

Krzysztof Mrózek

1 reference

Europe PubMed Central

3 August 2017

2

object named as

Kati Maharry

1 reference

Europe PubMed Central

3 August 2017

Christian Thiede

4

object named as

Christian Thiede

1 reference

Europe PubMed Central

3 August 2017

Richard A. Larson

8

object named as

Richard A Larson

1 reference

Europe PubMed Central

3 August 2017

6

object named as

Peter Paschka

1 reference

Europe PubMed Central

3 August 2017

author name string

Andreas Neubauer

1

1 reference

Europe PubMed Central

3 August 2017

Robert J Mayer

7

1 reference

Europe PubMed Central

3 August 2017

Edison T Liu

9

1 reference

Europe PubMed Central

3 August 2017

language of work or name

0 references

publication date

16 June 2008

1 reference

Europe PubMed Central

3 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

3 August 2017

26

1 reference

Europe PubMed Central

3 August 2017

4603-4609

1 reference

Europe PubMed Central

3 August 2017

28

1 reference

Europe PubMed Central

3 August 2017

Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653132

7 July 2018

Implications of NRAS mutations in AML: a study of 2502 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653132

7 July 2018

Oncogenic RAS induces accelerated transition through G2/M and promotes defects in the G2 DNA damage and mitotic spindle checkpoints

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653132

7 July 2018

RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653132

7 July 2018

Pathogenesis of acute myeloid leukaemia and inv(16)(p13;q22): a paradigm for understanding leukaemogenesis?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653132

7 July 2018

Targeting RAS signalling pathways in cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653132

7 July 2018

Comprehensive genotypic analysis of leukemia: clinical and therapeutic implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653132

7 July 2018

Cisplatin, cytarabine, caffeine, and continuously infused 5-fluorouracil (PACE) in the treatment of advanced pancreatic carcinoma: a phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653132

7 July 2018

The ras oncogene-mediated sensitization of human cells to topoisomerase II inhibitor-induced apoptosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653132

7 July 2018

Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653132

7 July 2018

Simple and sensitive detection of mutations in the ras proto-oncogenes using PNA-mediated PCR clamping

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653132

7 July 2018

Genetic alterations in the p53 gene in the blast crisis of chronic myelogenous leukemia: analysis by polymerase chain reaction based techniques

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653132

7 July 2018

N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653132

7 July 2018

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653132

7 July 2018

ras oncogenes in human cancer: a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653132

7 July 2018

N-ras mutations in adult de novo acute myelogenous leukemia: prevalence and clinical significance.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653132

7 July 2018

Ras triggers ataxia-telangiectasia-mutated and Rad-3-related activation and apoptosis through sustained mitogenic signaling.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653132

27 October 2018

Activation of the RAS pathway is predictive for a chemosensitive phenotype of acute myelogenous leukemia blasts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653132

27 October 2018

Oncogenic K-ras in mouse models of myeloproliferative disease and acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653132

27 October 2018

Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653132

27 October 2018

Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653132

27 October 2018

CYP1A1*2B (Val) allele is overrepresented in a subgroup of acute myeloid leukemia patients with poor-risk karyotype associated with NRAS mutation, but not associated with FLT3 internal tandem duplication.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653132

27 October 2018

FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653132

27 October 2018

N-ras gene point mutations in Brazilian acute myelogenous leukemia patients correlate with a poor prognosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653132

27 October 2018

Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653132

27 October 2018

Mutations in N-ras predominate in acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18559876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered

1 reference

https://pubmed.ncbi.nlm.nih.gov/18559876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The incidence and prognostic significance of mutations in codon 13 of the N-ras gene in acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18559876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes

1 reference

https://pubmed.ncbi.nlm.nih.gov/18559876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18559876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic significance of N-RAS and K-RAS mutations in 232 patients with acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18559876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ras oncogene-induced sensitization to 1-beta-D-arabinofuranosylcytosine

1 reference

https://pubmed.ncbi.nlm.nih.gov/18559876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/18559876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Advanced pancreatic cancer: a phase I-II trial of cisplatin, high-dose cytarabine, and caffeine

1 reference

https://pubmed.ncbi.nlm.nih.gov/18559876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2007.14.0418

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

3 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34593276&oldid=1746313410"